drugset / Trial / NCT05463224
Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients
NaSingle-groupOpen-labelTreatment
Summary
The primary objective is to evaluate the efficacy/safety of lazertinib and to explore the resistance mechanism of lazertinib as first-line in patients with NSCLC harboring activating EGFR mutations.
Timeline
- Start
- 2023-01-04
- Primary completion
- 2026-12-01
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lazertinib | Small molecule | 240 mg | Oral |